Protillion said that its platform enables commercial drug discovery partners to perform quantitative analysis on complete protein libraries, producing actionable insights in days rather than the months required using current industry best practices. The company said its technology can generate and analyze large experimental datasets at high amino acid resolution, enabling novel machine-learning approaches to antibody and binder discovery.

The funds will be used to scale up its hardware infrastructure and development teams to meet the demand for future partnerships in therapeutic antibody discovery. Protillion is currently identifying opportunities to accelerate discovery processes for potential pharmaceutical partners through its technology.

Protillion's technology approaches for drug discovery unite an array of interdisciplinary fields, including protein engineering, next-generation sequencing technology, molecular biology, in vitro transcription and translation, computational biology, software development, and various engineering disciplines.

"For the first time, quantitative binding measurements for millions of biologic candidates can be seen upfront, and big data is available much earlier in the discovery process," Protillion co-founder and CEO Curtis Layton said in a statement.